Sight Sciences

Sight Sciences

Developer of glaucoma implants for the treatment of irreversible blindness.

HQ location
San Francisco, United States
Launch date
Market cap
$222m
Enterprise value
$154m
Share price
$4.13 SGHT
Authorizing premium user...